在皮下肿瘤异种移植研究中评估固定剂量药物组合的相互作用。
Assessing interactions for fixed-dose drug combinations in subcutaneous tumor xenograft studies.
作者信息
Wu Jianrong
机构信息
Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
出版信息
Pharm Stat. 2013 May-Jun;12(3):115-9. doi: 10.1002/pst.1559. Epub 2013 Mar 7.
Abstract
Drug combinations in preclinical tumor xenograft studies are often assessed using fixed doses. Assessing the joint action of drug combinations with fixed doses has not been well developed in the literature. Here, an interaction index is proposed for fixed-dose drug combinations in a subcutaneous tumor xenograft model. Furthermore, a bootstrap percentile interval of the interaction index is also developed. The joint action of two drugs can be assessed on the basis of confidence limits of the interaction index. Tumor xenograft data from actual two-drug combination studies are analyzed to illustrate the proposed method.
摘要
临床前肿瘤异种移植研究中的药物组合通常采用固定剂量进行评估。关于评估固定剂量药物组合的联合作用，在文献中尚未得到充分发展。在此，针对皮下肿瘤异种移植模型中的固定剂量药物组合提出了一种相互作用指数。此外，还开发了该相互作用指数的自助百分位数区间。可以基于相互作用指数的置信限来评估两种药物的联合作用。对实际两药组合研究的肿瘤异种移植数据进行分析以说明所提出的方法。
相似文献
1
Assessing interactions for fixed-dose drug combinations in subcutaneous tumor xenograft studies.在皮下肿瘤异种移植研究中评估固定剂量药物组合的相互作用。
Pharm Stat. 2013 May-Jun;12(3):115-9. doi: 10.1002/pst.1559. Epub 2013 Mar 7.
2
Assessing interactions for fixed-dose drug combinations in tumor xenograft studies.评估肿瘤异种移植研究中固定剂量药物组合的相互作用。
J Biopharm Stat. 2012;22(3):535-43. doi: 10.1080/10543406.2011.556285.
3
A predictive pharmacokinetic-pharmacodynamic model of tumor growth kinetics in xenograft mice after administration of anticancer agents given in combination.联合给予抗癌药物后异种移植小鼠肿瘤生长动力学的预测性药代动力学 - 药效动力学模型。
Cancer Chemother Pharmacol. 2013 Aug;72(2):471-82. doi: 10.1007/s00280-013-2208-8. Epub 2013 Jun 29.
4
Evaluating response to antineoplastic drug combinations in tissue culture models.在组织培养模型中评估对抗肿瘤药物组合的反应。
Methods Mol Med. 2005;110:173-83. doi: 10.1385/1-59259-869-2:173.
5
A minimal model of tumor growth inhibition in combination regimens under the hypothesis of no interaction between drugs.在药物之间不存在相互作用的假设下，联合方案中肿瘤生长抑制的最小模型。
IEEE Trans Biomed Eng. 2012 Aug;59(8):2161-70. doi: 10.1109/TBME.2012.2197680. Epub 2012 May 3.
6
A pre-clinical model of resistance to induction therapy in pediatric acute lymphoblastic leukemia.儿童急性淋巴细胞白血病诱导治疗耐药的临床前模型。
Blood Cancer J. 2014 Aug 1;4(8):e232. doi: 10.1038/bcj.2014.52.
7
Review of the application of response surface methodology in the combination therapy of cancer.响应面法在癌症联合治疗中的应用综述
Cancer Treat Rep. 1986 Jan;70(1):133-40.
8
Preclinical evaluation of drug combinations identifies co-inhibition of Bcl-2/XL/W and MDM2 as a potential therapy in uveal melanoma.药物组合的临床前评估确定 Bcl-2/XL/W 和 MDM2 的共同抑制作用是葡萄膜黑色素瘤的一种潜在治疗方法。
Eur J Cancer. 2020 Feb;126:93-103. doi: 10.1016/j.ejca.2019.12.012. Epub 2020 Jan 9.
9
Monitoring Dual VEGF Inhibition in Human Pancreatic Tumor Xenografts With Dynamic Contrast-Enhanced Ultrasound.用动态对比增强超声监测人胰腺肿瘤异种移植物中的双重 VEGF 抑制作用。
Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033819886896. doi: 10.1177/1533033819886896.
10
Can taxanes provide benefit in patients with CNS tumors and in pediatric patients with tumors? An update on the preclinical development of cabazitaxel.紫杉醇类药物能否使 CNS 肿瘤患者和儿童肿瘤患者获益？卡巴他赛的临床前开发进展更新。
Cancer Chemother Pharmacol. 2013 Sep;72(3):515-28. doi: 10.1007/s00280-013-2214-x. Epub 2013 Jul 3.
引用本文的文献
1
Radius additivity score: a novel combination index for tumour growth inhibition in fixed-dose xenograft studies.半径相加分数：固定剂量异种移植研究中肿瘤生长抑制的一种新型综合指标。
Front Pharmacol. 2023 Oct 13;14:1272058. doi: 10.3389/fphar.2023.1272058. eCollection 2023.
2
CombPDX: a unified statistical framework for evaluating drug synergism in patient-derived xenografts.CombPDX：一种用于评估患者来源异种移植物中药物协同作用的统一统计框架。
Sci Rep. 2022 Jul 29;12(1):12984. doi: 10.1038/s41598-022-16933-6.
3
Sequential Release of Paclitaxel and Imatinib from Core-Shell Microparticles Prepared by Coaxial Electrospray for Vaginal Therapy of Cervical Cancer.同轴电喷法制备紫杉醇和伊马替尼核壳型微球的序贯释放及其用于宫颈癌的阴道给药治疗。
Int J Mol Sci. 2021 Aug 16;22(16):8760. doi: 10.3390/ijms22168760.
本文引用的文献
1
Assessing interactions for fixed-dose drug combinations in tumor xenograft studies.评估肿瘤异种移植研究中固定剂量药物组合的相互作用。
J Biopharm Stat. 2012;22(3):535-43. doi: 10.1080/10543406.2011.556285.
2
Combination testing (Stage 2) of the Anti-IGF-1 receptor antibody IMC-A12 with rapamycin by the pediatric preclinical testing program.儿科临床前试验计划中，用雷帕霉素对 IGF-1 受体抗体 IMC-A12 进行联合检测（第 2 阶段）。
Pediatr Blood Cancer. 2012 May;58(5):729-35. doi: 10.1002/pbc.23157. Epub 2011 May 31.
3
Assessing cytotoxic treatment effects in preclinical tumor xenograft models.评估临床前肿瘤异种移植模型中的细胞毒性治疗效果。
J Biopharm Stat. 2009 Sep;19(5):755-62. doi: 10.1080/10543400903105158.
4
A semiparametric response surface model for assessing drug interaction.一种用于评估药物相互作用的半参数响应面模型。
Biometrics. 2008 Jun;64(2):396-405. doi: 10.1111/j.1541-0420.2007.00882.x. Epub 2007 Sep 26.
5
A generalized response surface model with varying relative potency for assessing drug interaction.一种用于评估药物相互作用的具有不同相对效价的广义响应面模型。
Biometrics. 2006 Dec;62(4):986-95. doi: 10.1111/j.1541-0420.2006.00579.x.
6
The pediatric preclinical testing program: description of models and early testing results.儿科临床前测试项目：模型描述及早期测试结果
Pediatr Blood Cancer. 2007 Dec;49(7):928-40. doi: 10.1002/pbc.21078.
7
Design and analysis of drug combination experiments.药物联合实验的设计与分析
Biom J. 2005 Jun;47(3):299-308. doi: 10.1002/bimj.200410124.
8
Experimental design and sample size determination for testing synergism in drug combination studies based on uniform measures.基于统一度量的药物联合研究中协同作用测试的实验设计与样本量确定
Stat Med. 2003 Jul 15;22(13):2091-100. doi: 10.1002/sim.1467.
9
Global tests for combination drug studies in factorial trials.析因试验中联合用药研究的全局检验
Stat Med. 1996 Feb 15;15(3):233-47. doi: 10.1002/(SICI)1097-0258(19960215)15:3<233::AID-SIM167>3.0.CO;2-H.
10
Testing for the existence of a desirable dose combination.检测是否存在理想的剂量组合。
Biometrics. 1993 Mar;49(1):85-94.
Zotero 插件